PT  - JOURNAL ARTICLE
AU  - Bergstedt, Jacob
AU  - Pasman, Joëlle A.
AU  - Ma, Ziyan
AU  - Harder, Arvid
AU  - Yao, Shuyang
AU  - Parker, Nadine
AU  - Treur, Jorien L.
AU  - Smit, Dirk J.A.
AU  - Frei, Oleksandr
AU  - Shadrin, Alexey
AU  - Meijsen, Joeri J.
AU  - Shen, Qing
AU  - Hägg, Sara
AU  - Tornvall, Per
AU  - Buil, Alfonso
AU  - Werge, Thomas
AU  - Hjerling-Leffler, Jens
AU  - Als, Thomas D.
AU  - Børglum, Anders D.
AU  - Lewis, Cathryn M.
AU  - McIntosh, Andrew M.
AU  - Valdimarsdóttir, Unnur A.
AU  - Andreassen, Ole A.
AU  - Sullivan, Patrick F.
AU  - Lu, Yi
AU  - Fang, Fang
TI  - Distinct genomic signatures and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease
AID  - 10.1101/2023.09.01.23294931
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2023.09.01.23294931
4099  - http://medrxiv.org/content/early/2024/01/29/2023.09.01.23294931.short
4100  - http://medrxiv.org/content/early/2024/01/29/2023.09.01.23294931.full
AB  - Major depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in excess morbidity and mortality. Using genomic data, this study elucidates biological mechanisms, key risk factors, and causal pathways underlying their comorbidity. We show that CVDs share a large proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of the shared genetic liability between MDD and atherosclerotic CVD (ASCVD) revealed seven novel loci and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial/lifestyle risk factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not from most CVDs to MDD, and demonstrated that the causal effects were partly explained by metabolic and psychosocial/lifestyle factors. The distinct signature of MDD-ASCVD comorbidity aligns with the idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD. In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well as key modifiable risk factors for prevention of CVD in individuals with MDD.Competing Interest StatementCML sits on the SAB of Myriad Neuroscience and has received speaker/consultancy fees from SYNLAB and UCB.Funding StatementThis work was supported by European Union's Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant #847776). JAP was supported by the the US National Institutes of Mental Health (R01MH123724). NP was supported by the Marie Skłodowska-Curie Actions Grant 801133 (Scientia fellowship) and RCN 300309. JLT is supported by a European Research Council (ERC) Starting grant (UNRAVEL-CAUSALITY, grant number 101076686) and by Foundation Volksbond Rotterdam. CML is part-funded the NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), the EU H2020 Program (Grant No. 667302, "CoCA"), NIH/NIMH (1R01MH124851-01). OA was supported by the European Union's Horizon 2020 research and innovation program (grant agreement No 847776 and 964874), Research Council of Norway (223273, 296030, 326813). PFS gratefully acknowledges support from the Swedish Research Council (Vetenskapsrådet, award D0886501), the US National Institutes of Mental Health (R01s MH124871, MH121545, and MH123724), and the Horizon 2020 Programme of the European Union (grant agreement No 847776). LY was supported by the European Research Council (grant agreement ID 101042183). The authors acknowledge HERMES and CARDIoGRAMplusC4D consortia for contributing data and guidance.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data for this work was published genome-wide association study summary statistics that were publicly available before the initiation of the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes